Skip to main content
. 2017 Aug 1;8(51):88501–88516. doi: 10.18632/oncotarget.19762

Figure 2. VNPT-178 and VNLG-74A antagonize the fAR and promote its depletion.

Figure 2

(A) Androgen-dependent luciferase expression was determined in LNCaP and 22Rv1 cells transiently co-transfected with ARR2-Luc and pRL-null reporters. Plot represents mean RLU fold-change ± SEM of three independent experiments. (B) Western blots of AR and PSA expression in LNCaP and 22Rv1 cells 48 hours after treatment with indicated compounds. (C) LNCaP and (D) 22Rv1 cells treated with increasing doses of VNPT-178 or VNLG-74A for 24 hours exhibit differences in AR, PSA, and cleaved caspase-3 expression. Densitometry of total AR and PSA immunoblots are plotted as the mean fold-change ± SEM of three replicate assays. (E) VNPT-178 and VNLG-74A uniquely promote PARP cleavage in LNCaP cells after 48 hours.